Stanford
http://www.stanfordgroup.com/#Stanford provides institutional investment services and private wealth management services. The firm also offers equity research to its clients in the consumer, media, energy, financial, healthcare, technology and water/environment sectors.
View Older Stories View More Recent Stories
-
Tetraphase Pharma (TTPH) Names Larry Tsai M.D. as Chief Medical Officer
-
Imperva (IMPV) Announces Mike Burns as CFO
-
VeriFone Systems (PAY) Appoints Dr. Ronald Black and Mr. Larry Klane to Board
-
Sina Corp (SINA) Names James Jianzhang Liang to Board
-
Cypress Semiconductor (CY) Names Jeannine Sargent to Board
-
WideOpenWest (WOW) Says Teresa Elder has Joined Company as CEO
-
AveXis (AVXS) Reports Plan to Commence Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101
-
Flexion Therapeutics (FLXN) Names Scott Kelley, M.D. as Chief Medical Officer
-
Alpine Management Systems, Inc. (ALPN) Reports Preclinical Data on Novel Immuno-Oncology Molecules from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells
-
Amber Road (AMBR) Appoints Ralph Faison to Board
-
Jazz Pharmaceuticals (JAZZ) Names Daniel Swisher As President And COO
-
Glu Mobile (GLUU) Appoints Gabrielle Toledano to Board
-
Sunesis Pharmaceuticals (SNSS) Names William Quinn as CFO
-
Merrimack (MACK) Names George Demetri M.D. to Board
-
Macrogenics (MGNX) Appoints Dr. Jay Siegel to Board
-
Lincoln National (LNC) Appoints Lynn Utter to Board
-
Alpine Management Systems, Inc. (ALPN) Reports Preclinical Data on Novel Immuno-Oncology Molecules
-
Illumina (ILMN) Names Gary Guthart to its Board of Directors
-
Eli Lilly & Co. (LLY) Says Long-Term Use of Taltz Shows Efficacy Improvements in PsA at ACR/ARHP
-
B. Riley FBR, Inc. Expands Energy and Natural Resources Team with New Senior Level Research Professionals
-
Intuit Names Diego Rodriguez as Chief Product and Design Officer
-
Ternium SA (TX) Says Maximo Vedoya to Succeed Daniel Novegil as CEO
-
TG Therapeutics (TGTX) Reports Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS at ECTRIMS - ACTRIMS
-
TG Therapeutics (TGTX) Announces Updated Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS
-
ATARA Biotherapeutics (ATRA) Says Six of Ten Progressive MS Patients Experienced Clinical Improvements in Ongoing Phase 1 Study of Autologous ATA190
-
Alphatec Holdings (ATEC) Announces Prelim. Q3 Results
-
Stanford Bioengineering Professor to Head Medical Imaging Journal in 2018
-
ATARA Biotherapeutics (ATRA) Reports Two Publications of Updated Interim Results from a Phase 1 Study of Autologous ATA190
-
Beazley partners with The Risk Authority Stanford to enhance hospital claims data
-
Adamas Pharma (ADMS) Names Mardi Dier to Board
-
Build-A-Bear Foundation Gives 20,000 Teddy Bears To Children's Hospitals Across The Country In Partnership With United Way And UPS
-
Report that Tesla (TSLA) Model 3 is Being Made By Hand is 'Crazy'
-
Stanford Releases Annual Financial Results for Investment Return, Endowment
-
Stanford Neuroscientist, Robert Malenka, M.D., Ph.D., to Advise Cerevance
-
DayOne Baby Launches Breast Pump Rental Program for New Moms in Conjunction with the Roth Auxiliary Gift Shop at Lucile Packard Children's Hospital Stanford
-
Sorrento Therapeutics (SRNE) Names Dorman Followwill & Dave Lemus to Board
-
NCI Building Systems (NCS) Says Norman C. Chambers to Step Down as Chairman; James S. Metcalf to Succeed
-
UPDATE: TG Therapeutics (TGTX) Secures Grant from National Multiple Sclerosis Society to Support Development of TGR-1202 (Umbralisib) as Oral B-cell Targeted Treatment Option
-
AveXis (AVXS) to Begin Pivotal Trial of AVXS-101 in SMA Type 1 Using Product from New GMP Commercial Process
-
Aduro Biotech (ADRO) Reports First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD
-
Fibrocell Science (FCSC) Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for RDEB
-
Lean Enterprise Institute Executives Will Speak at Stanford #Lean Healthcare Conference
-
Cree (CREE) Names Gregg Lowe as CEO
-
Asterias Biotherapeutics (AST) Reports AST-OPC1 Clinical Trial Will Continue Following Recommendation of Data Monitoring Committee
-
22nd Century Group (XXII) Says It's Free of Restrictive License Agreement with BAT
-
Aristeia Capital Nominates Two to Sina (SINA) Board
-
TG Therapeutics (TGTX) Says Phase 3 ULTIMATE Trials Evaluating TG-1101 in Patients with RMS Are Now Open for Enrollment
-
AC Immune SA (ACIU) Completes Recruitment in Study of Trial for anti-Abeta Vaccine Targeting AD-like Characteristics in Individuals with DS
-
AbbVie (ABBV) Reports Upadacitinib (ABT-494) Meets All Primary & Ranked Secondary Endpoints in Second Phase 3 Study
-
Pfizer (PFE) Reports Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin (trastuzumab) at ESMO 2017

